AVITA Medical (RCEL) director receives RSU and stock option awards
Rhea-AI Filing Summary
AVITA Medical, Inc. director Robert McNamara reported receiving new equity compensation. He was granted 22,214 restricted stock units, each representing one share of common stock, subject to time-based vesting. These RSUs vest 12 months after the January 20, 2026 grant date, following stockholder approval obtained on June 3, 2026.
McNamara was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share. The options were approved by the board on January 5, 2026, have a grant date of January 20, 2026, become exercisable starting January 20, 2027, and expire on January 20, 2036. Following these awards, he directly owns 108,985 shares of common stock, including unvested RSUs.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 22,214 shares
Net Buy
2 txns
Insider
McNamara Robert
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 16,133 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 22,214 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options (Right to Buy) — 16,133 shares (Direct);
Common Stock — 108,985 shares (Direct)
Footnotes (3)
- F1. Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date of January 20, 2026. This grant of RSUs was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
- F2. Includes unvested RSUs.
- F3. On January 5, 2026, the Board of Directors approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors, with a grant date of January 20, 2026 (the "Grant Date") and an exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77. This option grant was subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.
Key Figures
RSUs granted: 22,214 RSUs
RSU vesting: 12 months after grant
Options granted: 16,133 options
+4 more
7 metrics
RSUs granted
22,214 RSUs
Award of restricted stock units granted January 20, 2026
RSU vesting
12 months after grant
RSUs vest 12 months after January 20, 2026
Options granted
16,133 options
Stock options granted with January 20, 2026 grant date
Option exercise price
$3.77 per share
Exercise price equals Nasdaq closing price on grant date
Option exercisable from
January 20, 2027
Exercise start date for stock options
Option expiration
January 20, 2036
Expiration date of stock options
Shares held after awards
108,985 shares
Total direct common stock holdings including unvested RSUs
Key Terms
restricted stock units (the "RSUs"), time-based vesting criteria, exercise price, non-executive directors, +1 more
5 terms
restricted stock units (the "RSUs") financial
"Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share"
time-based vesting criteria financial
"that are subject to time-based vesting criteria. These RSUs vest on the date 12 months following the grant date"
exercise price financial
"with a grant date of January 20, 2026 and an exercise price equal to the closing price of a share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
non-executive directors financial
"approved a grant of 16,133 options to acquire 16,133 shares of Common Stock to each of its non-executive directors"
Non-executive directors are board members who do not work for the company day-to-day but oversee management, like an independent referee watching a game rather than playing. They matter to investors because they provide impartial checks on executive decisions, help shape long-term strategy, monitor risks and financial reporting, and guard shareholder interests—contributing to better governance and reducing the chance of mismanagement or conflicts of interest.
Nasdaq financial
"exercise price equal to the closing price of a share of Common Stock on Nasdaq on the Grant Date of $3.77"
The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did AVITA Medical (RCEL) report for Robert McNamara?
AVITA Medical reported equity awards to director Robert McNamara, including new restricted stock units and stock options. These are compensation-related grants, not open-market trades, and increase his potential ownership in the company over time as they vest and become exercisable.
How many RSUs did AVITA Medical (RCEL) grant to director Robert McNamara?
Robert McNamara received an award of 22,214 restricted stock units from AVITA Medical. Each RSU represents a contingent right to one share of common stock, subject to time-based vesting conditions that must be satisfied before the underlying shares are actually issued.
When do Robert McNamara’s AVITA Medical (RCEL) RSUs vest?
The RSUs granted to Robert McNamara vest 12 months after the January 20, 2026 grant date. Vesting is time-based, meaning he must remain eligible through that period, and the grant was specifically conditioned on stockholder approval obtained on June 3, 2026.
What stock options did AVITA Medical (RCEL) grant to Robert McNamara?
AVITA Medical granted Robert McNamara 16,133 stock options to acquire 16,133 common shares. These options have a grant date of January 20, 2026, an exercise price of $3.77 per share, and give him the right to buy shares at that price before expiration.
What is the exercise price and term of Robert McNamara’s AVITA Medical (RCEL) options?
The options have an exercise price of $3.77 per share, set at the Nasdaq closing price on the January 20, 2026 grant date. They become exercisable starting January 20, 2027 and expire on January 20, 2036, giving a long-dated potential purchase window.